商品编号


3450-048-SK



品牌


Trevigen



公司


Trevigen, Inc



公司分类


Cell Based Assays



Size

48 Tests

商品信息

Description

DIVAA
?
is the first
in vivo
system for the study of angiogenesis that provides quantitative and reproduc
IBL
e results. During the course of the assay, implant grade silicone cylinders closed at one end, called angioreactors, are filled with 20 μl of
Trevigen
’s PathClear? basement membrane extract (BME) premixed with or without angiogenic-modulating factors*. These angioreactors are then implanted subcutaneously in the dorsal flank of nude mice. Accompanied with the onset of angiogenesis, vascular endothelial cells proceed to grow into the BME and form vessels in the angioreactor. As early as nine days post-implantation, there are enough cells to determine an effective dose response to angiogenic modulating factors. The sleek design of the angioreactor provides a standardized platform for reproduc
IBL
e and quantifiable
in vivo
angiogenesis assays. Compared to the plug assay, the angioreactor prevents assay errors due to absorption of the basement membrane extract by the mouse. In addition, the angioreactor uses only a fraction of the materials conserving both BME and test compounds used, and up to four angioreactors may be implanted in each mouse, allowing for greater statistical power.
Trevigen
’s DIVAA has been used in a variety of investigations.

* The PathClear? designation means:


No bacterial or fungal growth detected after incubation at 37°C for 14 days following
USP
XXIV Chapter 71 sterility test.

Negative by PCR test for: mycoplasma, 17 bacterial and virus strains typically included in mouse antibody production (MAP) testing, plus 13 additional murine infectious agents including LDEV, for a total of 31 organisms and viruses.





Catalog # 3450-048-SK includes :



Catalog Number

Description

Qty



3450-048-02

DIVAA BME

1



3450-048-04

DIVAA FGF-2 Positive Control

1



3450-048-05

DIVAA Cell Sperse

1



3450-048-B10





DIVAA FGF-2 (1800ng)/ VEGF (600ng)





1



3450-048-01

DIVAA Angioreactor

1



3450-048-09





DIVAA AngioRack





1



3450-048-03

DIVAA Wash Buffer

1



3450-048-06

DIVAA FITC-Lectin 200X

1



3450-048-07

25X FITC-Lectin Diluent

1



3450-048-08

Heparin Solution

1




“Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the
Expression of Interleukin-6 and Vascular Endothelial Growth Factor A
in Colon Cancer Cells and Induce Angiogenesis”
“Ai-Chung Mar, Chun-Ho Chu, Hui-Ju Lee, Chia-Wen Chien, Jing-Jy Cheng, Shung-Haur Yang, Jeng-Kai
Jiang, and Te-Chang Lee”
J. Biol. Chem., Sep 2015; 290: 22212 – 22224.
http://www.jbc.org/cgi/content/abstract/290/36/22212